This site is under development. For the current active site, go to bcbhub.csic.es.

Orcid Publication

Detalle de: Discovery and Biochemical Characterization of Plasmodium Thioredoxin Reductase Inhibitors from an Antimalarial Set

Title Discovery and Biochemical Characterization of Plasmodium Thioredoxin Reductase Inhibitors from an Antimalarial Set
Abstract

Plasmodium falciparum is the most prevalent and deadly species of the human malaria parasites, and thioredoxin reductase (TrxR) is an enzyme involved in the redox response to oxidative stress. Essential for P. falciparum survival, the enzyme has been highlighted as a promising target for novel antimalarial drugs. Here we report the discovery and characterization of seven molecules from an antimalarial set of 13533 compounds through single-target TrxR biochemical screens. We have produced high-purity, full-length, recombinant native enzyme from four Plasmodium species, and thioredoxin substrates from P. falciparum and Rattus norvegicus. The enzymes were screened using a unique, high-throughput, in vitro native substrate assay, and we have observed selectivity between the Plasmodium species and the mammalian form of the enzyme. This has indicated differences in their biomolecular profiles and has provided valuable insights into the biochemical mechanisms of action of compounds with proven antimalarial activity.

Apa Reference Theobald, A.J., Caballero, I., Coma, I., Colmenarejo, G., Cid, C., Gamo, F., Hibbs, M.J., Bass, A.L. & Thomas, D.A. (2012). Discovery and Biochemical Characterization of Plasmodium Thioredoxin Reductase Inhibitors from an Antimalarial Set. Biochemistry, 51(23), 4764-4771. 10.1021/bi3005076
Doi 10.1021/bi3005076
Publication Date 1 Jun 2012
Publication Type Article
Researcher Gonzalo Colmenarejo
Ontology Drug Discovery and design
Research Groups
Tools

Suggest changes

Publications are synced automatically from ORCID, so they can't be edited here directly. Spotted something wrong? Let us know below and we'll take care of it.

← Return to Home